Patents by Inventor David Lee LAMPI HERMANSON

David Lee LAMPI HERMANSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240294664
    Abstract: This disclosure describes chimeric antigen receptors for expression in a Natural Killer (NK) cell, pharmaceutical compositions that include NK cells (and/or iPSCs) modified to express a chimeric antigen receptor, and methods involving such chimeric antigen receptors. Generally, the chimeric antigen receptor includes an ectodomain that includes an antigen recognition region, a transmembrane domain linked to the ectodomain, and an endodomain linked to the transmembrane domain. The endodomain can include a signaling peptide that activates an NK cell.
    Type: Application
    Filed: May 9, 2024
    Publication date: September 5, 2024
    Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Dan Samuel Kaufman, David Lee Lampi Hermanson, Branden Scott Moriarity
  • Patent number: 12030953
    Abstract: This disclosure describes chimeric antigen receptors for expression in a Natural Killer (NK) cell, pharmaceutical compositions that include NK cells (and/or iPSCs) modified to express a chimeric antigen receptor, and methods involving such chimeric antigen receptors. Generally, the chimeric antigen receptor includes an ectodomain that includes an antigen recognition region, a transmembrane domain linked to the ectodomain, and an endodomain linked to the transmembrane domain. The endodomain can include a signaling peptide that activates an NK cell.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: July 9, 2024
    Assignee: Regents of the University of Minnesota
    Inventors: Dan Samuel Kaufman, David Lee Lampi Hermanson, Branden Scott Moriarity
  • Publication number: 20200291125
    Abstract: This disclosure describes chimeric antigen receptors for expression in a Natural Killer (NK) cell, pharmaceutical compositions that include NK cells (and/or iPSCs) modified to express a chimeric antigen receptor, and methods involving such chimeric antigen receptors. Generally, the chimeric antigen receptor includes an ectodomain that includes an antigen recognition region, a transmembrane domain linked to the ectodomain, and an endodomain linked to the transmembrane domain. The endodomain can include a signaling peptide that activates an NK cell.
    Type: Application
    Filed: April 1, 2020
    Publication date: September 17, 2020
    Inventors: Dan Samuel KAUFMAN, David Lee LAMPI HERMANSON, Branden Scott MORIARITY
  • Patent number: 10640570
    Abstract: This disclosure describes chimeric antigen receptors for expression in a Natural Killer (NK) cell, pharmaceutical compositions that include NK cells (and/or iPSCs) modified to express a chimeric antigen receptor, and methods involving such chimeric antigen receptors. Generally, the chimeric antigen receptor includes an ectodomain that includes an antigen recognition region, a transmembrane domain linked to the ectodomain, and an endodomain linked to the transmembrane domain. The endodomain can include a signaling peptide that activates an NK cell.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: May 5, 2020
    Assignee: Regents of the University of Minnesota
    Inventors: Dan Samuel Kaufman, David Lee Lampi Hermanson, Branden Scott Moriarity
  • Publication number: 20180002438
    Abstract: This disclosure describes chimeric antigen receptors for expression in a Natural Killer (NK) cell, pharmaceutical compositions that include NK cells (and/or iPSCs) modified to express a chimeric antigen receptor, and methods involving such chimeric antigen receptors. Generally, the chimeric antigen receptor includes an ectodomain that includes an antigen recognition region, a transmembrane domain linked to the ectodomain, and an endodomain linked to the transmembrane domain. The endodomain can include a signaling peptide that activates an NK cell.
    Type: Application
    Filed: January 28, 2016
    Publication date: January 4, 2018
    Inventors: Dan Samuel KAUFMAN, David Lee LAMPI HERMANSON, Branden Scott MORIARITY